ArriVent BioPharma, Inc. (AVBP): Total Liabilities
$25.95M
As of 2025-12-31
$27.88M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.95M | +50.1% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $17.29M | +46.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $11.80M | n/a | 2025-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $25.95M | +50.1% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $27.39M | -5.1% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $53.23M | -17.4% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Liquidia Corp (LQDA) | 2025-12-31 | $283.19M | +87.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $213.39M | +126.2% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $46.33M | -23.0% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $91.85M | -15.0% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $19.12M | +0.1% |
Compare AVBP, AMLX, RCKT, KROS side by side · Screen every company in Pharmaceutical Preparations ↗